unreported offer in mid-December for the company. However, the Ablynx board rejected this offer the same day, explaining that the price undervalued the business. Ultimately ,Novo lost out to Sanofi who bid $4.8 billion. Later, in the same year the company announced it would acquire Ziylo for around $800 million. 2020 In March, Novo volunteers started testing samples for SARS-CoV-2 with RT-qPCR equipment in the ongoing coronavirus pandemic to increase available test capacity. In June, the business announced it would acquire AstraZeneca's spin-off Corvidia Therapeutics for an initial sum of $725 million (up to a performance-related maximum of $2.1 billion), boosting its presence in cardiovascular diseases. In November, the company announced it would acquire Emisphere Technologies for $1.8 billion, gaining control of a pill-based treatment for diabetes. In December, Novo announced it would acquire Emisphere Technologies for $1.35 billion. 2021 In November, Novo announced it would acquire Dicerna Pharmaceuticals and its RNAi therapeutics, for $3.3 billion ($38.25 per share). Toxicogenomics Novo Nordisk is involved in government funded collaborative research projects with other industrial and governmental partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox. The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of European Federation of Pharmaceutical Industries and Associations and the European Commission. Diabetic work Novo Nordisk founded the World Diabetes foundation to save the lives of those affected by diabetes in developing countries and supported a UN (United Nations) resolution to fight diabetes, making diabetes is the only other disease along with HIV / AIDS to have a commitment to combat at a UN level. Diabetic treatments account for 85% of Novo Nordisk’s business. Novo Nordisk works with doctors, nurses, and patients, to develop products for self-managing diabetes conditions. The DAWN (Diabetes Attitudes, Wishes and Needs) 2001 study was a global survey of the psychosocial aspects of living with diabetes. It involved over 5,000 people with diabetes and almost 4,000 care providers. This study was designed to identify barriers to optimal health and quality of life. A follow-up study completed in 2012 involved more than 15,000 people living with, or caring for, those with diabetes. In response to British findings, a National Action Plan (NAP) was developed, with a multidisciplinary steering committee, to support the delivery of individualised person-focused care in the United Kingdom. The NAP seeks to provide a holistic approach to